Vascular endothelial growth factor inhibitor-induced hypertension: basics for primary care providers. - Wikidata - wikimedia - TriplyDB

Vascular endothelial growth factor inhibitor-induced hypertension: basics for primary care providers.

Vascular endothelial growth factor inhibitor-induced hypertension: basics for primary care providers.

http://www.wikidata.org/entity/Q34996468

about

Angiogenic inhibitors for older patients with advanced colorectal cancer: does the age hold the stage?Long-term suppression of ocular neovascularization by intraocular injection of biodegradable polymeric particles containing a serpin-derived peptide Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring.A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients.Endothelin-1 and antiangiogenesis.Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib.Predictors of anti-VEGF drug-induced hypertension using different hypertension criteria: a secondary analysis of the COMPARZ study.Navigating Systemic Therapy in Advanced Thyroid Carcinoma: From Standard of Care to Personalized Therapy and Beyond

P2860

Q27002538-E2BA218F-8A79-41F3-BFB2-3E87C1B8A5B2 Q34816580-300BEF30-25CB-405B-8DB2-6E82FC5AA061 Q35783911-CB666A58-BBBC-4BAF-99DB-FB114BB546AA Q36508942-B8A1CDE6-32D8-4E34-ABFA-A54E5986EAEA Q38378485-3C16B233-31AB-4439-898D-7269A4F7C826 Q38618814-69535A1A-8546-496B-9E0B-0CDBC08AC270 Q39474625-5D183E2F-3140-4674-B0CA-BF94B02A611C Q49635743-06550DF4-B102-4EDC-8CA3-8AB262E58DC8 Q58784257-DEBA7FDC-909A-41A9-8230-3E2AB8429D7B

P2860

Vascular endothelial growth factor inhibitor-induced hypertension: basics for primary care providers.

http://www.wikidata.org/entity/Q34996468

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Vascular endothelial growth fa ...... cs for primary care providers.

@ast

Vascular endothelial growth fa ...... cs for primary care providers.

@en

Vascular endothelial growth fa ...... cs for primary care providers.

@nl

type

label

Vascular endothelial growth fa ...... cs for primary care providers.

@ast

Vascular endothelial growth fa ...... cs for primary care providers.

@en

Vascular endothelial growth fa ...... cs for primary care providers.

@nl

prefLabel

Vascular endothelial growth fa ...... cs for primary care providers.

@ast

Vascular endothelial growth fa ...... cs for primary care providers.

@en

Vascular endothelial growth fa ...... cs for primary care providers.

@nl

P1433

Q34996468-AE9249BA-F000-4576-95ED-9A7EA2B97642

P1476

Q34996468-342D50DB-FBBD-4D43-8DCF-D618975D5AC6

P2093

Q34996468-33BBB0C7-F4A0-4D3E-A4E0-CA7226ED2B2D

Q34996468-6E1176F3-5D33-4C77-BA9B-002385C2A653

P2860

Q34996468-06EBF7A2-251E-4FCB-B2D3-C343E7218981

Q34996468-0FC701D4-140E-432D-8CFE-C5544CAEF2AE

Q34996468-184B10EF-8C93-4DEA-A486-7CF7C98AB322

Q34996468-21A67860-88E4-45C3-A727-1AB72A5A4150

Q34996468-22FE1F04-EC5E-4011-A642-7844E0BA2259

Q34996468-253AF5E3-2432-4ACF-B0C7-D1C1A08CE96A

Q34996468-26104455-EA9C-486F-9BF6-EB6E7303E354

Q34996468-2B2FEB71-1FD3-4656-B14C-339333B11F93

Q34996468-48191F46-B7F4-4EFD-8FDA-67BD45968527

Q34996468-4CD5BEB8-D2FB-42DB-A99C-0F7FFFE45B18

P304

Q34996468-68194381-172E-4596-A803-494CC2A84A5C

P31

Q34996468-D8C258F8-1CAC-4FFE-B97C-273BAFDB6BBC

P356

Q34996468-31EE9674-A064-439D-9CF7-5E340E20CAD3

P478

Q34996468-910CA26B-FAEC-4F11-8495-10D476C6611F

P577

Q34996468-72105E02-0C28-49BB-A7B4-47373A6CD943

P5875

Q34996468-9A36841A-E785-4624-9771-146ADCE12A82

P698

Q34996468-C31E5A63-C5B8-4122-98BF-CA92CEB708E3

P921

Q34996468-C1015962-39BD-40DF-8289-DA0605D58D97

P932

Q34996468-75B8705C-1636-4853-9C80-41BC52BB21AD

P356

P1433

Cardiology Research and Practice

P1476

Vascular endothelial growth fa ...... cs for primary care providers.

@en

P2093

Ali Zalpour

http://www.w3.org/2001/XMLSchema#string

Carmen P Escalante

http://www.w3.org/2001/XMLSchema#string

P2860

Tumor angiogenesis: therapeutic implications

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report

Angiogenesis in cancer, vascular, rheumatoid and other disease

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

Tumorigenesis and the angiogenic switch

Drug-induced prolongation of the QT interval.

Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor.

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.

Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

P304

816897

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4061/2011/816897

http://www.w3.org/2001/XMLSchema#string

P478

2011

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51181595

http://www.w3.org/2001/XMLSchema#string

P698

21629798

http://www.w3.org/2001/XMLSchema#string

P921

P932

3099203

http://www.w3.org/2001/XMLSchema#string